The theory's attractive, but a new test still needs to be validated.
Despite advances in HIV treatment, we are still struggling to create efficient algorithms for diagnosis, particularly during the early weeks of infection when standard antibody tests can be negative. The protocols in most public health venues involve antibody testing followed by batched nucleic-acid amplification testing, but this sequence can take days or even weeks to yield final results for individual specimens.
In a recent manufacturer-supported trial, investigators evaluated the performance of a “fourth-generation” enzyme immunoassay (EIA) that simultaneously tests for HIV-1/2 antibodies and p24 antigen. A total of 3318 specimens were obtained from individuals tested at public sexually transmitted infection clinics in North Carolina. Tw…
Reviewing Author
DisclosuresNothing to disclose
DisclosuresNothing to disclose